Among 370 patients who underwent the radical resection of primary colorectal cancer over a 17-year period, 114 had stage III-Dukes'C cancer. After excluding 10 patients treated intravenously with drugs other than 5-FU or with hepatic arterial injection and 9 patients who had uncommon tumors other than typical differentiated adenocarcinoma, the remaining 95 patients were investigated to assess the utility of Japanese-style oral postoperative adjuvant immunochemotherapy for stage III colorectal cancer. Sixty-one patients received postoperative oral chemotherapy with or without immunotherapy and had a 5-year survival rate of 60.7%, while the survival rate was only 48.8% for patients without such therapy (p=0.0136). When the 61 patients were further divided into those treated with chemotherapy plus immunotherapy (immuno-chemotherapy; n=38) and those treated with chemotherapy alone (chemotherapy-only; n=23), the 5-year survival rates of the immunochemotherapy, chemotherapy-only, and non-chemotherapy groups were 62.7%, 57.4%, and 48.8%, respectively (immunochemotherapy vs. non-chemotherapy, p=0.0172). The 5-year survival rate was also calculated for 69 patients whose background factors were matched by the propensity score matching method and a significant difference was found between the immunochemotherapy and non-chemotherapy groups (p=0.0265). These results suggest that Japanese-style oral immunochemotherapy is useful as postoperative adjuvant therapy for stage III-Dukes'C colorectal cancer.
Introduction
Along with the recent trend for westernization of the diet and lifestyle, the incidence of primary colorectal cancer has been increasing in Japan. The mortality due to colorectal cancer has tended to increase in both men and women: it is the fourth most common cause of cancer death after lung, gastric, and liver cancer in men, while it has increased rapidly to take the second place after gastric cancer in women (Health and Welfare Statistics Association, 2001 ). The national survey performed by the Japanese Society for Cancer of the Colon and Rectum revealed that patients who underwent radical resection of stage III-Dukes'C colon cancer with lymph node metastasis had a 5-year stage of rectal cancer (Japanese Society for Cancer of the Colon and Rectum, 2002) .
This indicates that about 30 to 40% of patients who undergo radical resection will suffer from life-threatening metastasis and/or recurrence, although this is a better result than reported in the USA (Jessup, McGinnis, et al., 1996; Jessup, Stewart, el al., 1998) . The difference is probably related to the progress in surgery and to the development of various postoperative adjuvant therapies, which are employed in addition to the chemotherapy and radiotherapy used in Western countries. In Japan as well as in 216 VOLUME 11, NOS. Western countries, intravenous administration of anticancer drugs, such as 5-fluorouracil (5-FU)+Leucovorin (LV), is often done to treat patients with stage III primary colorectal cancer (Laurie, Moertel, et al., 1989; Moertel, Fleming, et al., 1990) . Additionally, an oral fluoropyrimidine preparation (5-FU, UFT, 5'-DFUI, HCFU, etc.) is often administered as postoperative adjuvant chemotherapy on an outpatient basis after intravenous 5-FU+LV therapy has been completed (The Colorectal Cancer
Chemotherapy Study Group of Japan, 1995; Sakamoto, Hamada, et al., 2001; Muto, Koyama, et al., 2002; Kato, Ohashi, et al., 2002) . Among the various oral fluoropyrimidine preparations, Orzel (UFT+LV, Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) has been approved and widely marketed in Europe (Mukai, Moriya, et al., 2001; Douillard, Hoff, et al., 2002; Carmichael, Popiela, et al., 2002) . Currently, analysis of data on stage II and III colorectal cancer is being performed as part of a prospective randomized controlled trial of this drug in the USA (NSABP, C-06 study).
The combination of a fluoropyrimidine preparation with PSK (Kureha Chemical Industry Co., Ltd., Tokyo, Japan), which is the only oral immunomodulatory and immunoactivating agent approved for colorectal cancer in Japan, has been widely used to treat both stage II and stage III patients (Takashima, Kinami, et al., 1988; Torisu, Hayashi, et al., 1990; Mitomi, Tsuchiya, et al., 1992; Mitomi, Tsuchiya, et al., 1993; Nakazato, Ito, et al., 1999) . Unlike leucovorin, which modulates the metabolism of 5-FU drugs, PSK is a preparation that increases nonspecific immunity when administered orally on an outpatient basis without causing myelosuppression such as leucopenia and pancytopenia, abdominal discomfort, or diarrhea. The effect of this immunomodulator has already been studied extensively in patients with stage III cancer. However, about 10 years have passed since the initial clinical report on oral immunochemotherapy for Dukes'C cancer patients was published.
The aim of this study was to re-evaluate the recent clinical outcome of Japanese-style oral immunochemotherapy when used as postoperative adjuvant therapy in patients with stage III-Dukes'C primary colorectal cancer. The compliance and eligibility were assessed on the basis of the medical records by relative performance which was the ratio of the actual total dose taken to the total dose prescribed, with approximately more than 70% during a period of 6 months, 1-year and 2-year, respectively (Nakajima, Okabayashi, et al., 1989) . To evaluate the utility of postoperative adjuvant chemotherapy, the 5-year survival rate was calculated for 61 patients who took an oral fluoropyrimidine preparation (5-FU; 150-300mg/day, or UFT; years with or without immunotherapy, chemotherapy group) and for 34 patients who received no chemotherapy (non-chemotherapy group). The clinicopathological characteristics of the two groups were not significantly different, except for their age (p=0.0028, Table I ).
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The 61 patients in the chemotherapy group were further divided into 38 patients immunochemotherapy group) and 23 patients who did not receive PSK therapy (chemotherapy-only group), and a comparison of their 5-year survival rates was performed. Clinicopathological characteristics were not significantly different among all three groups, except for their age (p=0.0113, Table II ).
To confirm the reliability of these results, 5-year survival rate was also calculated for 69 patients (23 patients from each group) selected by the propensity score matching method, in whom all of the background factors were matched (Rubin and Thomas N, 1996; D'Agostino, 1998) .
Statistical analysis
To assess the 5-year survival rates, the Kaplan-Meier method was used. The log-rank test was used to compare the chemotherapy group including patients treated with PSK and the non-chemotherapy group, the relative risk was also estimated (95% T, U, and H tests, as well as analysis of variance (ANOVA). A P value of less than 0.05 was considered to indicate a significant difference in all analyses. The statistical software used was SPSS 11.0 J (SPSS Japan, Inc., Tokyo, Japan).
Results
The 5-year survival rate was 96.5% in Dukes' stage A (n=89), 88.6% in stage B (n=167), and 57.5% in stage C (n=114), showing a significant difference between stages Aand C (p<0.0001) as well as between stages B and C (p<0.0001) (Figure 1 ).
When the 5-year survival rate was calculated, it was 60.7% in the chemotherapy group including patients treated with PSK and 48.8% in the non-chemotherapy group (p=0.0136, Figure 2 ).
When the chemotherapy group was divided into patients treated with chemotherapy + immunotherapy (immunochemotherapy group) and those treated with chemotherapy alone (chemotherapy-only group), the 5-year survival rates of the immunochemotherapy , chemotherapy-only, and non-chemotherapy groups were 62.7%, ANNALS OF Cancer Research and Therapy Figure 1 : The five-year survival rate in relation to Dukes' clinical stage . The survival rate was 96.9% for Dukes' A patients (n=89) , 88.6% for Dukes'B patients (n=167), and 57.5% for Dukes'C patients (n=114) , with a significant difference between Dukes' stages A and C (p<0.0001) and between Dukes' stages B and C (p<0 .0001). The 5-year survival rate of the immunochemotherapy (n=38), chemotherapy-only (n=23), and non-chemotherapy (n=34) groups was 62.7%, 57.4%, and 48.8%, respectively (immunochemotherapy vs. chemotherapy-only group; p=0.5609, immunochemotherapy vs. non-chemotherapy group; p=0.0172, and chemotherapy-only vs. non-chemotherapy group; p=0.1532).
Figure 4:
The 5-year survival rates of 3 groups consisting of 23 patients each selected by the propensity score matching method was 64.9% in the immunochemotherapy group, 57.4% in the chemotherapy-only group, and 46.8% in the non-chemotherapy group (immunochemotherapy vs . chemotherapy-only group; p=0.5093, immunochemotherapy vs . non-chemotherapy group; p=0.0265, and chemotherapy-only vs. non-chemotherapy group; p=0.1107). Figure 3 ).
ANNALS
The 5-year survival rates for the 3 groups of 23 patients selected by the propensity score matching method were 64.9%, 57.4%, and 46.8%, respectively (immunochemotherapy vs. chemotherapy-only group; p=0.5093, immunochemotherapy vs. non-chemotherapy group; p=0.0265, and chemotherapy-only vs. non-chemotherapy group; p=0.1107, Figure 4 ).
Discussion
Treatment with 5-FU+LV has been established as the gold standard of postoperative adjuvant chemotherapy for patients with stage III-Dukes'C cancer and lymph node metastasis in Japan, as is the case in Western countries (Laurie, Moertel, et al., 1989; Moertel, Fleming, et al., 1990) . There are various regimens, including once-a-week bolus injection for 4 to 6 weeks and continuous administration for 5 days once a month, and most treatment schedules are continued for about 5 to 6 months postoperatively (Machover, Schwarzenberg, et al., 1982; Petrelli, Douglass, et al., 1989; O'connell, 1989; De Gramont, Bosset, et al., 1997) . Since 1999, we have performed high-dose 5-FU+LV therapy, involving intravenous administration (IV) for 5 consecutive days per month, in Dukes'C patients up to 75 years old, with about 6 months of treatment as 1 course (Machover, Schwarzenberg, et al., 1982) . The subjects of the present study consisted of 37 IV/DIV (+) and 58 IV/DIV (-) patients, with a mean age of (+) patients was probably smaller because our subjects included many elderly patients.
Oral fluoropyrimidine preparations seem likely to achieve more widespread use as easily administered postoperative adjuvant chemotherapy with few adverse reactions for the dramatically increasing number of elderly patients in the future.
Although intravenous administration of 5-FU+LV has been established as the standard first-line therapy for primary colorectal cancer, several studies have shown that oral UFT+LV (Orzel) can achieve comparable efficacy and greater safety in patients ANNALS OF Cancer Research and Therapy with metastatic colorectal cancer (Douillard, Hoff, et al., 2002; Carmichael, Popiela, et al., 2002) . UFT is a 5-FU derivative that contains tegafur and uracil. It is an oral anti-cancer agent with a stronger anti-tumor activity than 5-FU, because uracil blocks the degradation of active 5-FU released from tegafur. We have already reported a regimen for advanced colorectal cancer in which UFT and PSK is administered from Monday to Friday followed by a drug-free weekend, which we called the weekly 5-method (Mukai, Tokunaga, et al., 2000) . This regimen has the advantage of allowing patients to relax at the weekend without the need to take drugs, which may help to improve compliance.
PSK is a protein-bound polysaccharide obtained from the mycelia of Coriolus versicolor, and is an immunoactivator that inhibits tumor growth by maintaining and enhancing host immunity (Takashima, Kinami, et al., 1988; Torisu, Hayashi, et al., 1990; Mitomi, Tsuchiya, et al., 1992; Mitomi, Tsuchiya, et al., 1993; Nakazato, Ito, et al., 1999) .
This protein-polysaccharide complex has a molecular weight of about 100,000 and a protein content of 38%, while glucose accounts for about 75% of the carbohydrate component. The mechanisms of action of PSK are becoming better understood through molecular-biological studies and are known to include the following: 1) direct cytotoxicity for cancer cells, 2) induction of host immune cells and cytokines, and 3) inhibition of immunosuppressants that are produced in the tumor-bearing state (Fujii, 1996) . PSK is thought to cause a shift from the dominance of humoral immunity (Th2), which is often seen in cancer patients, towards dominance of cellular immunity (Th1), which is considered to be responsible for the anti-tumor activity (Shibata, Nezu, et al., 2002) . PSK may be able to induce the transformation of lymphocytes by combining with lectin-like sugars and stimulating adhesion of the complex to lymphocyte membranes, and it may also promote macrophage chemotaxis (Fujii, 1996) . This may also occur in patients with stage III-Dukes'C cancer, provided that their immune function is relatively well maintained. One study has shown that serum IgA and IgM levels were increased before palliative surgery in terminal patients with stage IV cancer who responded well to immunochemotherapy (Mukai, Tokunaga, et al., 2000) . However, it still is unclear whether high preoperative immunoglobulin levels can be used as a clinical The present study demonstrated the utility of Japanese-style oral immunochemotherapy as postoperative adjuvant therapy in patients with stage III primary colorectal cancer. It seems that oral chemotherapy agents should be combined with the biological response modifier PSK to increase their effectiveness when administered on an outpatient basis after the completion of intravenous therapy or when used to treat elderly patients.
